Clinical Application of Artificial Oocyte Activation Technique (AOA) in ART
NCT ID: NCT04519918
Last Updated: 2020-09-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
400 participants
INTERVENTIONAL
2020-10-01
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Artificial Oocyte Activation
NCT06290895
Assessment of Follicular Fluid Level of Coenzyme Q10 in Women Undergoing ICSI
NCT04515134
Successful Pregnancy and Delivery After AOA
NCT01595815
Autologous Platelet-rich Plasma to Improve Responsiveness and Embryo Quality in Patients With Poor Ovarian Response
NCT05105724
Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders
NCT05181748
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
When the number of retrieved oocytes was \>10, sibling oocytes were divided into 3 groups to perform the standard ICSI procedure (control group), chemical AOA (A1 experiment group) or mechanical AOA (A2 experiment group). When the number of retrieved oocytes was 6-10, sibling oocytes were randomized 1:1 to perform the chemical AOA (A1 experiment group) or mechanical AOA (A2 experiment group). The number of retrieved oocytes was 1-5, all oocytes were perform the chemical AOA. Control group, a single spermatozoon was injected into the ooplasm, standard ICSI procedure. A1 experiment group, were treated by injecting CaCl2 concurrently with ICSI followed by sequential exposure of calcium ionophore A23187 activation solution for two times of post-ICSI AOA. A2 experiment group, mechanical stimulation was done before standard ICSI procedure, then the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA. The investigators want to establish the effective and safe of different AOA methods, to improve the fertilization outcome and embryo quality, and finally obtain healthy offspring.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard ICSI procedure
a single spermatozoon was injected into the ooplasm.
No interventions assigned to this group
Chemical oocyte activation
After CaCl2 was injected, the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.
AOA
AOA represents an invasive non-physiological technique.
Mechanical oocyte activation
Mechanical stimulation was done before standard ICSI procedure, then the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.
AOA
AOA represents an invasive non-physiological technique.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AOA
AOA represents an invasive non-physiological technique.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patients suffered at least 2 cycles complete fertilization failure or low fertilization rate after performing IVF in previous cycle. Low fertilization was defined as less than 33% fertilization rate.
* The sperm of the patients has the following characteristics: globozoospermia, acrosomal deletion or small, severe head deformity, etc.
* Sperm of testicular origin and/or sperm that has been freeze-thawed.
* The sperm was PLC-ΞΆ missing.
* The MII oocytes were IVM cultured and/or freeze-thawed.
* The patients suffered at least 2 cycles no available embryos, because of the embryo development block or fragmentation.
Exclusion Criteria
22 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tang-Du Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Li Bo, Doctor
Role: STUDY_CHAIR
Reproductive Medicine Center, Tangdu Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tangdu Hospital
Xi'an, Shaanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
wang ming
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AOA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.